ZA85206B - Protein conjugates useful in the treatment of thrombotic disease - Google Patents

Protein conjugates useful in the treatment of thrombotic disease

Info

Publication number
ZA85206B
ZA85206B ZA85206A ZA85206A ZA85206B ZA 85206 B ZA85206 B ZA 85206B ZA 85206 A ZA85206 A ZA 85206A ZA 85206 A ZA85206 A ZA 85206A ZA 85206 B ZA85206 B ZA 85206B
Authority
ZA
South Africa
Prior art keywords
treatment
protein conjugates
thrombotic disease
conjugates useful
useful
Prior art date
Application number
ZA85206A
Other languages
English (en)
Inventor
Harry Ferres
Richard Anthony Godwin Smith
Andrew John Garman
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of ZA85206B publication Critical patent/ZA85206B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA85206A 1984-01-11 1985-01-09 Protein conjugates useful in the treatment of thrombotic disease ZA85206B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848400653A GB8400653D0 (en) 1984-01-11 1984-01-11 Conjugates

Publications (1)

Publication Number Publication Date
ZA85206B true ZA85206B (en) 1986-04-30

Family

ID=10554819

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA85206A ZA85206B (en) 1984-01-11 1985-01-09 Protein conjugates useful in the treatment of thrombotic disease

Country Status (8)

Country Link
US (1) US4673573A (xx)
EP (1) EP0152736A3 (xx)
JP (1) JPS60174724A (xx)
AU (1) AU3754285A (xx)
ES (1) ES8602118A1 (xx)
GB (1) GB8400653D0 (xx)
GR (1) GR850067B (xx)
ZA (1) ZA85206B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334499D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Derivatives
US5256413A (en) * 1985-01-08 1993-10-26 The General Hospital Corporation Method and use for site-specific activation of substances
NZ217844A (en) * 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
US5089406A (en) * 1987-01-07 1992-02-18 Allied-Signal Inc. Method of producing a gene cassette coding for polypeptides with repeating amino acid sequences
GB8705377D0 (en) * 1987-03-07 1987-04-08 Beecham Group Plc Compounds
GB8707369D0 (en) * 1987-03-27 1987-04-29 Beecham Group Plc Enzyme derivatives
US5009888A (en) * 1987-04-13 1991-04-23 Genzyme Corporation Therapeutic enzyme-antibody complexes
GB8711957D0 (en) * 1987-05-20 1987-06-24 Beecham Group Plc Compounds
GB8715302D0 (en) * 1987-06-30 1987-08-05 Ordidge R J Nmr spectroscopy
EP0297882B1 (en) * 1987-07-01 1993-08-25 Beecham Group Plc Hybrid plasminogen activators
US5302390A (en) * 1987-07-01 1994-04-12 Beecham Group Plc Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5225540A (en) * 1988-04-26 1993-07-06 Du Pont Merck Pharmaceutical Company Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US6007817A (en) 1988-10-11 1999-12-28 University Of Southern California Vasopermeability enhancing immunoconjugates
EP0395918A3 (en) * 1989-04-13 1991-10-23 Vascular Laboratory, Inc. Plasminogen activator complex of pure pro-urokinase covalently bound by a disulfide bridge to human serum albumin
CA1335361C (en) * 1989-05-24 1995-04-25 Andrei Z. Budzynski Thrombus-targeted complexes of plasminogen activator and fibrin fragments
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
US5632986A (en) * 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
CA2062240A1 (en) * 1991-06-07 1992-12-08 Susan J. Danielson Labeled hydantoin derivatives for immunoassays
JP2606643B2 (ja) * 1992-04-01 1997-05-07 日東紡績株式会社 安息香酸アミジノフェニルエステル誘導体
ES2066733B1 (es) * 1993-06-30 1995-11-01 Antibioticos Farma S A Complejo consistente en un activador del plasminogeno y albumina de suero y procedimiento para prepararlo.
US5607841A (en) * 1994-06-20 1997-03-04 Lipinski; Boguslaw Preparation and proteolytic degradation of a macromolecular protein complex from fibrinogen
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
EP0937146A2 (en) * 1996-09-20 1999-08-25 The General Hospital Corporation Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
US5977313A (en) * 1996-10-10 1999-11-02 Quadrant Healthcare Limited Platelet substitutes and conjugation methods suitable for their preparation
GB0111420D0 (en) * 2001-05-10 2001-07-04 Biovector Solutions Ltd Soluble polymer systems for drug delivery
US7541159B2 (en) * 2004-04-14 2009-06-02 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Molecular-specific urokinase antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464468A (en) * 1968-03-29 1984-08-07 Agence Nationale De Valorisation De La Recherche (Anvar) Immobilization of active protein by cross-linking to inactive protein
US4082612A (en) * 1976-09-24 1978-04-04 Michael Reese Research Foundation Plasminogen activator complex
US4134792A (en) * 1976-12-06 1979-01-16 Miles Laboratories, Inc. Specific binding assay with an enzyme modulator as a labeling substance
SE427505B (sv) * 1977-03-04 1983-04-11 Pharmacia Diagnostics Ab Reagens till anvendning vid immunkemiska bestemningsmetoder
JPS5411219A (en) * 1977-06-25 1979-01-27 Green Cross Corp:The Thrombolytic agent and its preparation
EP0000938B1 (en) * 1977-08-22 1984-10-17 National Research Development Corporation Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them
NZ191320A (en) * 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions
US4305926A (en) * 1979-09-13 1981-12-15 Johannes Everse Immobilization of Streptokinase
EP0028489B1 (en) * 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
DE3361610D1 (en) * 1982-04-07 1986-02-06 Beecham Group Plc Enzyme derivatives, process for preparing them and pharmaceutical compositions containing them
US4530900A (en) * 1982-09-13 1985-07-23 Seragen Diagnostics Inc. Soluble insoluble polymers in enzymeimmunoassay
EP0109653A3 (en) * 1982-11-17 1986-01-29 Otsuka Pharmaceutical Co., Ltd. Process for preparing urokinase complex
SU1128601A1 (ru) * 1983-05-10 1985-07-15 Всесоюзный кардиологический научный центр АМН СССР Урокиназа,иммобилизированна на фибриногене
JPS60136520A (ja) * 1983-12-23 1985-07-20 Otsuka Pharmaceut Co Ltd フイブリン吸着性ウロキナ−ゼ複合体
GB8334499D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Derivatives

Also Published As

Publication number Publication date
ES539432A0 (es) 1985-11-01
US4673573A (en) 1987-06-16
EP0152736A3 (en) 1986-12-10
JPS60174724A (ja) 1985-09-09
GB8400653D0 (en) 1984-02-15
ES8602118A1 (es) 1985-11-01
AU3754285A (en) 1985-07-18
EP0152736A2 (en) 1985-08-28
GR850067B (xx) 1985-05-16

Similar Documents

Publication Publication Date Title
ZA85206B (en) Protein conjugates useful in the treatment of thrombotic disease
EP0205579A4 (en) METHODS AND COMPOSITIONS FOR USE IN THE DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES.
IL73883A0 (en) Cytotoxic protein
JPS6447796A (en) Alkylglucoside and manufacture
GB8602672D0 (en) Protein modification
EP0310057A3 (en) Decoder
PH25327A (en) Binfunctional proteins
JPS6487537A (en) Transparent body and manufacture
ZA842051B (en) Galactosyl-insulin conjugates useful in treating diabetics
DE3760670D1 (en) Improvements in the manufacture of curved glass
SG30547G (en) Cosmetic
ZA859008B (en) The treatment of tumors in mammals
AR243936A1 (es) Procedimiento para desamargar proteinas hidrolizadas enzimaticamente las proteinas asi desamargadas, procedimiento para obtener un producto con sabor a carne a partir de dicho hidrolizado.
GB2177398B (en) 5,6-epoxy-7-oxabicycloheptane substituted ethers useful in the treatment of thrombotic disease
GB8822532D0 (en) Improvements in forceps
GB2203645B (en) Improvements in the treatment of hair
GB2208310B (en) Improvements in or relating to the identification of pipeline sections
GB2200733B (en) Improvements in or relating to showers
PH25614A (en) Shampoo composition
ZA887364B (en) Ovulation treatment
GB9008215D0 (en) Improvements in or relating to the treatment of surfaces
GB2207163B (en) Improvements in or relating to kerbs
GB8713559D0 (en) Structural proteins
GB8725462D0 (en) Protein
EP0295893A3 (en) Ultrasonic analyzers